
In Moscow, the majority of the population has already developed immunity to COVID-19, and if revaccination is necessary, this can be done with any component of the Sputnik V vaccine, RBC was told in the Moscow Department of HEALTH.
Earlier, on the official portal of the mayor and government of the capital, it was reported that the first component of the Russian CORONAVIRUS vaccine Sputnik V, the EpiVacCorona, KoviVac and Sputnik Light vaccines are not available in Moscow.
In response to a request from RBC, the Department of Health recalled that revaccination is possible with any component of the Sputnik V vaccine, and in Moscow, by now, and taking into account mass vaccination, the majority of the population has developed immunity to infection.
“For a new course of revaccination against coronavirus, any of the components of the Sputnik V vaccine (including only the second one) can be used. At the same time, the delivery of the first component of the vaccine from the Ministry of Health is expected,” the press service said.
The first component of the Sputnik V vaccine has ended in Moscow Society
According to the Russian operational headquarters, as of March 4, almost 90 million people were fully vaccinated against coronavirus, the level of herd immunity in RUSSIA is 7.4%, while in Moscow it is 1.9%. Over the past day, 14,049 new COVID-19 infections have been detected in the country, and 39 more people have died. At the same time, 2.3 thousand fell ill in the capital, and ten people died.
In August 2020, Russia was the first in the world to register a vaccine against coronavirus - Sputnik V, developed by the Research Center for Epidemiology and Microbiology. N.F. Gamaleya. The vaccine consists of two components based on adenovirus vectors 26 and 5. RDIF stated that the effectiveness of Sputnik V, based on the analysis of data from 3.8 million vaccinated Russians, was 97.6%. Vaccination is carried out in two components.
"EpiVacKorona" was developed by FBU "Vector" and released into civilian circulation since January 2021. This is a one-component vaccine based on peptide antigens - short pieces of SARS-CoV-2 coronavirus proteins that contribute to the production of antibodies in the body. Vaccine "KoviVac" of the Center. Chumakova was registered in Russia at the end of February 2021, it is based on an inactivated (or killed) whole SARS-CoV-2 virus.
How the number of hospitalizations with coronavirus in Moscow changes March 3 The number of hospitalized and detected cases per day, data taken from autumn 2021